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Abstract 
Purpose: To describe acute respiratory distress syndrome (ARDS) severity, ventilation management, and the out-
comes of ICU patients with laboratory-confirmed COVID-19 and to determine risk factors of 90-day mortality post-ICU 
admission.
Methods: COVID-ICU is a multi-center, prospective cohort study conducted in 138 hospitals in France, Belgium, and 
Switzerland. Demographic, clinical, respiratory support, adjunctive interventions, ICU length-of-stay, and survival data 
were collected.
Results: From February 25 to May 4, 2020, 4643 patients (median [IQR] age 63 [54–71] years and SAPS II 37 [28–50]) 
were admitted in ICU, with day-90 post-ICU admission status available for 4244. On ICU admission, standard oxygen 
therapy, high-flow oxygen, and non-invasive ventilation were applied to 29%, 19%, and 6% patients, respectively. 
2635 (63%) patients were intubated during the first 24 h whereas overall 3376 (80%) received invasive mechanical 
ventilation (MV) at one point during their ICU stay. Median (IQR) positive end-expiratory and plateau pressures were 
12 (10–14)  cmH2O, and 24 (21–27)  cmH2O, respectively. The mechanical power transmitted by the MV to the lung was 
26.5 (18.6–34.9) J/min. Paralyzing agents and prone position were applied to 88% and 70% of patients intubated at 
Day-1, respectively. Pulmonary embolism and ventilator-associated pneumonia were diagnosed in 207 (9%) and 1209 
(58%) of these patients. On day 90, 1298/4244 (31%) patients had died. Among patients who received invasive or non-
invasive ventilation on the day of ICU admission, day-90 mortality increased with the severity of ARDS at ICU admis-
sion (30%, 34%, and 50% for mild, moderate, and severe ARDS, respectively) and decreased from 42 to 25% over the 
study period. Early independent predictors of 90-day mortality were older age, immunosuppression, severe obesity, 
diabetes, higher renal and cardiovascular SOFA score components, lower  PaO2/FiO2 ratio and a shorter time between 
first symptoms and ICU admission.
Conclusion: Among more than 4000 critically ill patients with COVID-19 admitted to our ICUs, 90-day mortality was 
31% and decreased from 42 to 25% over the study period. Mortality was higher in older, diabetic, obese and severe 
ARDS patients.
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Introduction
From March to May 2020, Europe was massively affected 
by the coronavirus disease 2019 (COVID-19) outbreak. 
In that context, the REVA network [1] designed a specific 
registry (COVID-ICU), to prospectively collect charac-
teristics, management, and outcomes of patients admit-
ted to intensive care units (ICUs) for severe COVID-19 
in France, Belgium, and Switzerland. In France, as of 
October 1st, 2020, 395,104 patients had been tested posi-
tive for severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) and 32,365 deaths have been associ-
ated with the disease. On April 8, 2020, the number of 
COVID-19 patients hospitalized in French ICUs peaked 
at 7148.
A few case-series [2–5] have described baseline char-
acteristics and short-term mortality (up to 28-days after 
ICU admission) ranging from 26 to more than 50% in 
critically ill patients with COVID-19. However, recovery 
from severe COVID-19 often takes several weeks and a 
substantial number of these patients were still in the ICU 
or the hospital at the time their outcome was evaluated 
[4, 5]. Notably, 28-day mortality was 41% in the control 
care group of the RECOVERY trial, which showed that 
dexamethasone improved the survival of patients receiv-
ing invasive mechanical ventilation or oxygen at rand-
omization [6].
The present study reports data of 4244 patients with 
laboratory-confirmed SARS-CoV-2 infection admitted to 
the ICU and for whom day-90 status was available. We 
also evaluated risk factors associated with 90-day mortal-
ity in these critically ill patients.
Methods
Study Design, Patients
COVID-ICU is a multi-center, prospective cohort study 
conducted in 149 ICUs from 138 centers, across three 
countries (France, Switzerland, and Belgium). Centers 
were invited to participate by public announcements 
and by the Reseau European de recherche en Ventilation 
Artificielle (REVA) network (70 centers were active mem-
bers of this network). We included in the present report 
data from participating ICUs that had enrolled at least 
one patient with complete data on age and 90-day vital 
status. COVID-ICU received approval from the ethical 
committee of the French Intensive Care Society (CE-
SRLF 20–23) in accordance with our local regulations. 
All patients or close relatives were informed that their 
data were included in the COVID-ICU cohort.
All consecutive patients over 16  years of age admit-
ted to the participating ICU between February 25, 2020, 
and May 4, 2020, with laboratory-confirmed severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection were included. Laboratory confirmation for 
SARS-CoV-2 was defined as a positive result of real-time 
reverse transcriptase-polymerase chain reaction (RT-
PCR) assay from either nasal or pharyngeal swabs, or 
lower respiratory tract aspirates [7]. Patients without lab-
oratory-confirmed COVID-19 were not included, even if 
they presented with a typical radiological pattern.
Inclusions were stopped on May 4, 2020, after enroll-
ment of 4643 patients admitted to the ICU. Survival sta-
tus up to 90 days after ICU admission was obtained for 
4244 of them.
Data collection
Day 1 was defined as the first day when the patient was 
in ICU at 10 am. Each day, the study investigators com-
pleted a standardized electronic case report form. Base-
line information collected at ICU admission were: age, 
sex, body mass index (BMI), active smoking, Simplified 
Acute Physiology Score (SAPS) II score [8], Sequential 
Organ Failure Assessment (SOFA) [9], comorbidities, 
immunodeficiency (if present), clinical frailty scale [10], 
date of the first symptom, dates of the hospital and ICU 
admissions. The case report form prompted investiga-
tors to provide a daily-expanded data set including res-
piratory support devices (oxygen mask, high flow nasal 
cannula, or non-invasive ventilation), mechanical venti-
lation settings (positive end-expiratory pressure (PEEP), 
the fraction of inspired oxygen  (FiO2), respiratory rate, 
tidal volume, plateau pressure, arterial blood gas, stand-
ard laboratory parameters, and adjuvant therapies for 
acute respiratory distress syndrome (ARDS) such as 
the use of continuous neuromuscular blockers, nitric 
oxide, prone position, corticosteroids, or extracorpor-
eal membrane oxygenation until day-90. Driving pres-
sure was defined as plateau pressure minus PEEP and 
mechanical power (J/min) was calculated as follows: 
Mechanical power (J/min) = 0.098 × tidal volume × res-
piratory rate × (peak pressure − 1/2 × driving pres-
sure) [11]. If not specified, peak pressure was considered 
equal to plateau pressure. Ventilatory ratio was defined 
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as (minute ventilation × PaCO2) − (predicted body-
weight × 100 × 37.5) [12].
ARDS severity, complications, and outcomes
ARDS was graded based on the Berlin definition for 
patients undergoing mechanical ventilation (invasive or 
non-invasive) on ICU day 1 [13]. Patients on nasal, mask 
or high-flow oxygen therapy were not included in this 
group. However, their day-1  PaO2/FiO2 was calculated 
by converting  O2 flow to estimated  FiO2 (see conversion 
tables in the supplement) [14]. ICU-complications and 
organ dysfunction included acute kidney failure requir-
ing renal replacement therapy, thromboembolic compli-
cations (distal venous thrombosis or proven pulmonary 
embolism by either pulmonary CT angiography or car-
diac echography), ventilator-associated pneumonia, and 
cardiac arrest. Clinical suspicion of ventilator-associ-
ated pneumonia was confirmed before antibiotics either 
by quantitative distal bronchoalveolar lavage cultures 
growing ≥ 104  cfu/mL, blind protected specimen brush 
distal growing ≥ 103  cfu/mL, or endotracheal aspirates 
growing ≥ 106 cfu/mL.
Patient outcomes included the date of liberation from 
mechanical ventilation, dates of ICU and hospital dis-
charge, vital status at ICU and hospital discharge, and 28, 
60, and 90 days after ICU admission.
Statistical analyses
Characteristics of patients were described as frequencies 
and percentages for categorical variables and as means 
and standard deviations or medians and interquartile 
ranges for continuous variables. Categorical variables 
were compared by Chi-square or Fisher’s exact test, and 
continuous variables were compared by Student’s t test 
or Wilcoxon’s rank-sum test. Kaplan–Meier overall sur-
vival curves until Day 90 were computed, and were com-
pared using log-rank tests. The median length of stay in 
ICU and in hospital were also estimated using a Kaplan–
Meier estimator to take into account patients that may be 
still in ICU at the time of the analysis.
Baseline risk factors of death at Day 90 were assessed 
within the whole cohort using univariate and multivari-
ate cox regression. Baseline variables (i.e., obtained dur-
ing the first 24 h in the ICU) included in the multivariate 
model were defined a priori, and no variable selection 
was performed (see the description of the statistical 
analysis plan in the Supplement). ICU admission dates 
were split into four calendar periods (i.e., before March, 
15; from March 16 to 31; from April 1 to 15; and after 
April 16). Proportional hazard assumption was assessed 
by inspecting the scaled Shoenfeld residuals and Harrel’s 
test [15] (Table  S4). Multiple imputations were used to 
replace missing values when appropriate (Figure S1–S2). 
Ten copies of the dataset were created with the missing 
values replaced by imputed values, based on observed 
data including outcomes and baseline characteristics 
of participants. Each dataset was then analyzed and the 
results from each dataset were pooled into a final result 
using Rubin’s rule [16]. Lastly, a sensitivity analysis using 
a Cox model stratified on the center variable was also 
performed. Hazard ratios and their 95% confidence inter-
val were estimated. A p value < 0.05 was considered sta-
tistically significant. Statistical analyzes were conducted 
with R v3.5.1.
Results
Participating ICUs and Patients Enrolled
Patients were included in 149 ICUs (71 [48%] university, 
66 [44%] public regional, and 12 [8%] private, semi-pri-
vate, or military hospitals, respectively) from 138 centers 
in three countries. The median (interquartile) number of 
ICU beds in these centers and these ICUs were 26 (18-
55) and 20 (14-28), respectively. Fifty-six percent of the 
patients were recruited in Paris and the surrounding 
area (see Table S1-S3 in the Supplement for an extensive 
description of ICUs and center characteristics). Ninety-
four percent of the centers reported having extended the 
number of ICU beds during the COVID-19 outbreak.
Of the 4643 patients enrolled on May 4, 2020, 399 were 
lost to follow-up at Day-90. Thereafter we describe the 
characteristics of the remaining 4244 patients with avail-
able day-90 vital status (Fig. 1).
There were 1085/4244 (26%) female patients (Table 1). 
At ICU admission, their median (interquartile) age, SAPS 
II, and SOFA scores were 63 (54–71) years, 37 (28–50), 
and 5 (3–8), respectively. The rate of obese (BMI ≥ 30 kg/
m2) patients was 1607/3935 (41%). The most frequent 
comorbidities were hypertension 2018/4197 (48%), 
known diabetes 1167/4196 (28%), and immunocompro-
mised status 314/4192 (7%). Median (IQR) time between 
first symptoms and ICU admission was 9 (6–12) days. Of 
note, only 176/4124 (4%) patients were active smokers 
and only 208/4116 (5%) had concomitant bacterial pneu-
monia at ICU admission.
Ventilatory support, adjunctive therapies, and ARDS 
severity
On day-1, standard oxygen therapy, high flow oxygen, 
and non-invasive ventilation were applied to 1219/4157 
(29%), 786/4096 (19%), and 230/4109 (6%) patients, 
respectively. The use of these modalities tended to 
increase over time (Table S5 and Figure S3). 2635/4175 
(63%) were placed on invasive mechanical ventilation 
during the first 24 h, whereas in total 3376/4209 (80%) 
were intubated during their ICU stay. On the first day 
in ICU, median tidal volume, PEEP, plateau, driving 
pressures, and mechanical power were 6.1 (5.8–6.7) 
mL/kg, 12 (10–14)  cmH2O, 24 (21–27)  cmH2O, 13 
(10–17)  cmH2O, and 26.5 (18.6–34.9) J/min, respec-
tively (Table  1). 1841/2560 (72%) patients required a 
 FiO2 ≥ 50%, while 1371 (54%) received a PEEP ≥ 12 
 cmH2O.
Mild, moderate, and severe ARDS was reported in 
539/2233 (24%), 1154/2233 (52%), and 540/2233 (24%) 
patients on mechanical ventilation (invasive or non-
invasive) on ICU day 1, respectively (Table  2). Con-
tinuous neuromuscular blockade and prone position 
were used in 1966/2224 (88%), and 1556/2223 (70%) 
in these patients. Moderate and severe ARDS patients 
were more likely to receive these adjunct therapies, 
with a median number of 3 (IQR 2–6) prone position-
ing sessions per patient. Of note, 888/2224 (41%) of 
them received corticosteroids for a median of 5 (IQR 
2–8) days. Lastly, 321/4187 (8%) patients were placed 
on extracorporeal membrane oxygenation (ECMO). 
Table  S6 provides the use of adjunct therapies in the 
whole cohort of 4224 patients.
ICU complications and organ support in patients intubated 
on ICU‑day 1
Ventilator-associated pneumonia was diagnosed in 
1209/2101 (58%) patients who were intubated on ICU 
day 1, whereas 623/2227 (28%) patients had an acute 
kidney failure requiring renal replacement therapy 
Fig. 1 Flowchart of patients screening and inclusion. ICU intensive care unit
Table 1 Demographic, clinical, and ventilatory support characteristics of 4244 patients according to their 90‑day survival 
status
No. All patients
 (n = 4244)
90‑day status P value
Alive (n = 2946) Death (n = 1298)
Age, years, 4244 63 (54–71) 61 (52–69) 68 (59–74) < 0.001
Women, no (%) 4226 1085 (26) 771 (26) 314 (24) 0.170
Body mass index, kg/m2 3935 28 (25–32) 29 (26–32) 28 (25–32) 0.006
 ≥ 30 kg/m2 1607 (41) 1167 (42) 440 (37) 0.004
Active smokers 4124 176 (4) 116 (4) 60 (5) 0.234
SAPS II score 3935 37 (28–50) 34 (27–46) 44 (33–58) < 0.001
SOFA score at ICU admission 3676 5 (3–8) 4 (3–8) 7 (4–10) < 0.001
Treated hypertension 4197 2018 (48) 1310 (45) 708 (55) < 0.001
Known diabetes 4196 1167 (28) 704 (24) 463 (36) < 0.001
Immunodeficiencya 4192 314 (7) 178 (6) 136 (11) < 0.001
 Long-term  corticosteroidsb 4178 178 (4) 94 (3) 84 (7) < 0.001
Clinical frailty scale 3152 2 (2–3) 2 (2–3) 3 (2–4) < 0.001
Time between
 First symptoms to ICU admission, days 4007 9 (6–12) 9 (7–12) 8 (5–11) < 0.001
 ICU admission to invasive MV, hours 2010c 8 (1–27) 9 (1–27) 7 (1–29) 0.482
During the first 24 h in ICUb
Standard oxygen therapy 4157 1219 (29) 927 (32) 292 (23) < 0.001
High-flow oxygen 4096 786 (19) 584 (21) 202 (16) < 0.001
Noninvasive ventilation 4109 230 (6) 134 (5) 96 (8) < 0.001
Invasive mechanical ventilation 4175 2635 (63) 1678 (58) 957 (75) < 0.001
  PaO2/FiO2 2500 154 (106–223) 163 (116–229) 136 (91–206) < 0.001
  VT, mL/kg PBW 2306 6.1 (5.8–6.7) 6.1 (5.8–6.6) 6.1 (5.7–6.7) 0.652
  Set PEEP, cm  H2O 2542 12 (10–14) 12 (10–14) 12 (10–14) 0.429
  Plateau pressure,  cmH2O 1847 24 (21–27) 24 (21–26) 25 (21–28) < 0.001
  Driving pressure,  cmH2O
d 2256 13 (10–17) 12 (10–16) 14 (11–18) < 0.001
  Static compliance, mL/cmH2O
e 1746 33 (26–42) 34 (27–43) 32 (24–41) < 0.001
   < 30 635 (36) 367 (33) 268 (43) < 0.001
  30–39 562 (32) 380 (34) 182 (29)
   ≥ 40 549 (31) 376 (33) 173 (28)
  Dynamic compliance, mL/cmH2O
f 409 17 (14–25) 18 (14–26) 17 (13–22) 0.010
   Mechanical power, J/ming 1987 26.5 (18.6 –34.9) 26.1 (18.4–34.2) 27.1 (18.9–36.1) 0.120
   Ventilatory  ratioh 2251 1.7 (1.4–2.2) 1.7 (1.4–2.1) 1.8 (1.4–2.3) 0.017
Concomitant bacterial pneumonia 4116 208 (5) 138 (5) 70 (6) 0.298
Hemodynamic component of the SOFA, 4065 1 (0–4) 0 (0–3) 3 (0–4) < 0.001
Renal component of the SOFA, 4014 0 (0–1) 0 (0–0) 0 (0–1) < 0.001
Corticosteroidsi 4134 459 (11) 278 (10) 181 (14) < 0.001
Blood gases
  pH 4003 7.41 (7.34–7.46) 7.43 (7.36–7.47) 7.38 (7.30–7.44) < 0.001
  PaCO2, mmHg 4004 40 (35–46) 39 (35–45) 41 (35–49) < 0.001
  PaO2/FiO2
j 3080 154 (103–222) 162 (112–227) 134 (90–205) < 0.001
  HCO3, mmol/L 3942 25 (22–27) 25 (23–27) 24 (21–27) < 0.001
  Lactate, mmol/L 3795 1.2 (0.9–1.6) 1.2 (0.9–1.5) 1.3 (1.0–1.8) < 0.001
Biology
  Lymphocyte count, × 109/L 3481 0.8 (0.6–1.2) 0.8 (0.6–1.2) 0.8 (0.5–1.1) < 0.001
  Platelet count, × 109/L 3867 224 (167–291) 230 (176–299) 205 (151–271) < 0.001
  Total bilirubin, µmol/L 3029 10 (7–14) 10 (7–14) 10 (7–16) 0.210
  Serum creatinine, µmol/L 3915 78 (61–112) 73 (59–98) 94 (69–152) < 0.001
(Table  2). A venous thromboembolic complication 
was diagnosed in 373/2226 (17%) patients, of whom 
207/2226 (9%) had proven pulmonary embolism.
Patient outcomes and predictors of 90‑day mortality
Overall 90-day mortality was 31%. Within the first 
7  days after ICU admission, 64 (12%, 95 confidence 
interval [CI], 9–15%) patients with mild and 183 
(16%, 95 CI 14–18%) with moderate ARDS progressed 
to severe ARDS. In patients on mechanical ventila-
tion (invasive or non-invasive) at ICU day one, 90-day 
mortality was 820/2233 (37%), and increased with the 
severity of ARDS at ICU admission (30%, 34% and 
50% in mild, moderate, and severe ARDS patients, 
respectively) (Table  3 and Fig.  2). 90-day mortality 
was 292/1219 (24%), 202/786 (26%), and 96/230 (42%) 
in patients who received standard oxygen therapy, 
high flow oxygen, or non-invasive ventilation at day-
1. Noticeably, 90-day mortality declined over time 
from 42 to 25% (p < 0.001) in the first and the last 
period, respectively (Table S5 and Figure S3). Of note, 
90-day mortality was 36% in patients intubated dur-
ing their ICU stay and 11% for those not intubated (see 
Table S7). The overall median durations of mechanical 
ventilation, ICU, and hospital stay for 90-day survi-
vors were 13 (8–18), 21 (13–36), and 30 (20–48) days, 
respectively. Of note, these durations increased with 
the severity of the ARDS (Table 3).
Results of the multivariable analysis are reported in 
Table  4. After inspection of the proportional hazard 
assumption, a time-varying effect was introduced in the 
multivariate Cox model for four variables: body mass 
index, active smoking, renal component of the SOFA 
score, and lymphopenia. Thus, for these variables, two 
types of hazard ratio are reported, indicating the early 
effect (before 14  days of follow-up) or the late effect 
(after 15 days of follow-up) of the corresponding base-
line characteristic on the risk of death, respectively.
Non-survivors were older, and more frequently dia-
betic or immunocompromised than survivors. At ICU 
admission, they had a higher renal and hemodynamic 
SOFA component scores and lower  PaO2/FiO2 ratio. 
Interestingly, they also had a shorter time since the onset 
of the first symptoms. Day-1 patients’ characteristics sig-
nificantly associated with higher 90-day mortality identi-
fied by the Cox regression model were older age, known 
diabetes, class 2 and extreme obesity, immunodeficiency, 
higher renal and cardiovascular components of the SOFA 
score, lower  PaO2/FiO2, lower pH, and a shorter time 
between first symptoms and ICU admission (Table  4). 
The same analysis re-run after multiple imputations of 
missing data (Table  S8), and a sensitivity analysis intro-
ducing the center variable as a stratification variable in 
the multivariable model yielded similar results (Table S9). 
Kaplan–Meier survival estimates according to age, ICU 
admission period, the renal component of the SOFA 
score, the delay between the first symptoms and ICU 
admission, immunocompromised status, diabetes, severe 
lymphopenia, and static pulmonary compliance catego-
ries at day-1 are provided in Figs. 2b, S4-S10. Lastly, out-
comes of patients who progressed from mild to moderate 
or severe ARDS and those who progressed from moder-
ate to severe ARDS within the first week of mechanical 
ventilation are reported in Fig. 2c, d.
Table 1 (continued)
No. All patients
 (n = 4244)
90‑day status P value
Alive (n = 2946) Death (n = 1298)
  D-dimers, µg/L 1697 1600 (897–3690) 1450 (843–3212) 2200 (1127–5516) < 0.001
Results are expressed as n (%) or median (25th–75th percentiles)
FiO2 fraction of inspired oxygen, HCO3 bicarbonate, PEEP positive end-expiratory pressure, PaCO2 partial pressure of carbon dioxide, PBW predicted body weight, PaO2 
partial pressure of oxygen, SAPS simplified acute physiology score, SOFA Sequential Organ Failure Assessment, VT tidal volume
a Defined as hematological malignancies, active solid tumor, or having received specific anti-tumor treatment within a year, solid-organ transplant, human 
immunodeficiency virus, or immunosuppressants
b Several ventilation modalities could have been used during the first 24 h
c Time of intubation was available for 2010/3376 patients with invasive mechanical ventilation during their ICU stay
d Defined as plateau pressure—PEEP; If plateau pressure was missing, peak pressure was considered instead
e Defined as tidal volume/(Plateau pressure − PEEP)
f Defined as tidal volume/(Peak pressure − PEEP)
g Mechanical power (J/min) = 0.098 × tidal volume × respiratory rate × (peak pressure − 1/2 × driving pressure). If not specified, peak pressure was considered equal 
to plateau pressure
h Defined as (minute ventilation × PaCO2) − (predicted bodyweight × 100 × 37.5)
i Irrespective of the dose and the indication
j Calculated for all patients, including those on oxygen therapy using conversion tables provided in the online supplement
Discussion
We report herein one of the largest prospective case-
series of COVID-19 patients who required intensive care 
admission, with detailed information on their baseline 
characteristics, ARDS severity, and 90-day outcomes. 
Overall 90-day mortality was 31% and was higher in 
older and obese patients, diabetics, immunocompro-
mised patients, and those who had multiple organ dys-
function at ICU admission. 90-day mortality rates were 
30%, 34%, and 50%, in patients with mild, moderate, and 
severe ARDS who were on mechanical ventilation (inva-
sive or non-invasive) on ICU day-1, respectively. Notice-
ably, mortality rates decreased over time during the study 
period, while ICU and hospital length of stay were sub-
stantially longer than in other cohorts of ARDS patients 
[17].
Acute respiratory failure was the main indication for 
ICU admission, with 80% of our COVID-19 patients 
requiring invasive mechanical ventilation which is 
consistent with the experience in Lombardy, Italy 
[2], where 88% of ICU patients were intubated. How-
ever, lower rates of intubation in ICU patients were 
reported in Wuhan, China by Wang et  al. (47%), and 
Yang et al. (42%) [18, 19], and in Washington state, USA 
(71%) [20]. While early single-center reports in small 
groups of COVID patients reported well-preserved 
lung mechanics despite the severity of hypoxemia [21], 
more recent data [22] and our observations suggested 
that lung compliance and driving pressure were close to 
those of reported in classical ARDS. Mechanical power 
which is the energy delivered to the respiratory system 
over time during mechanical ventilation was very high 
in our patients with ARDS, reaching 26.5 (18.6–34.9) J/
min, while a higher mortality risk has been suggested 
for patients with ARDS whose value exceeded 17 J/min 
[23]. In that context, the application of evidence-based 
Table 2 Use of  adjunct measures, organ dysfunction and  major complications according to  acute respiratory distress 
syndrome severity for patients on mechanical ventilation (invasive or non‑invasive) on ICU day 1
Definition of abbreviations: ECMO extracorporeal membrane oxygenation. Results are expressed as n (%) or median (25th–75th percentiles)
a Only patients on invasive mechanical ventilation or non-invasive ventilation within the first 24 h in ICU
b Defined as 200 mmHg < PaO2/FIO2 ≤ 300 mmHg with PEEP ≥ 5 cm  H2O or continuous positive airway pressure ≥ 5 cm  H2O
c Defined as 100 mmHg < PaO2/FIO2 ≤ 200 mmHg with PEEP ≥ 5 cm  H2O
d Defined as  PaO2/FIO2 ≤ 100 mmHg with PEEP ≥ 5 cm  H2O
e Defined as plateau pressure—PEEP; If plateau pressure was missing, peak pressure was considered instead
f Defined as tidal volume/(plateau pressure − PEEP)
g Mechanical power (J/min) = 0.098 × tidal volume × respiratory rate × (peak pressure − 1/2 × driving pressure). If not specified, peak pressure was considered equal 
to plateau pressure
h Irrespective of the indication, the dose, and the timing
Parameter No. Alla 
(n = 2233)
Mild  ARDSb 
(n = 539)
Moderate  ARDSc 
(n = 1154)
Severe  ARDSd 
(n = 540)
P value
Ventilatory features on Day-1
 Plateau pressure,  cmH2O 1617 24 (21–27) 24 (21–26) 24 (21–27) 25 (22–28) <0.001
 Driving pressure,  cmH2O
e 1965 13 (10–17) 12 (10–15) 13 (10–18) 14 (11–18) <0.001
 Static compliance, mL/cmH2O
f 1531 33 (26–42) 36 (29–44) 33 (26–42) 30 (24–37) <0.001
 Mechanical power, J/ming 1735 26.6 (18.7–34.9) 24.9 (18.3–33.3) 26.4 (18.5–34.4) 29.1 (20.3–37.6) 0.001
Tracheotomy 2229 198 (9) 53 (10) 107 (9) 38 (7) 0.207
Prone position 2223 1556 (70) 308 (57) 822 (71) 426 (79) <0.001
 Number of session 1553 3 (2–6) 3 (2–6) 3 (2–6) 3 (2–6) 0.585
Continuous neuromuscular blockers 2224 1966 (88) 441 (82) 1025 (89) 500 (93) <0.001
Nitric oxide 2224 425 (19) 74 (14) 206 (18) 145 (27) <0.001
Corticosteroidsh 2224 888 (41) 192 (37) 458 (41) 238 (46) 0.012
ECMO 2153 235 (11) 41 (8) 111 (10) 83 (15) <0.001
Cardiac arrest 2227 133 (6) 31 (6) 58 (5) 44 (8) 0.038
Thromboembolic complications 2226 373 (17) 107 (20) 174 (15) 92 (17) 0.043
 Pulmonary embolism 207 (9) 59 (11) 95 (8) 53 (10) 0.872
 Proven distal venous thrombosis 184 (8) 54 (10) 89 (8) 41 (8) 0.567
Renal replacement therapy 2227 623 (28) 135 (25) 320 (28) 168 (31) 0.080
Bacterial coinfection 1951 144 (7) 24 (5) 84 (8) 36 (8) 0.062
Ventilator-associated pneumonia 2101 1209 (58) 276 (54) 628 (58) 307 (61) 0.084
ARDS care, such as lung-protective mechanical ven-
tilation and proning are both warranted [24]. ECMO, 
which was used in 15% of severe ARDS in our cohort 
should be considered when these measures have failed 
[25].
28-day mortality was 39% in 257 critically-ill COVID-
19 patients in New-York city, of whom 203 (79%) received 
invasive mechanical ventilation [4], 41% in patients on 
invasive mechanical ventilation included in the usual 
care group of the RECOVERY randomized trial [6] 
and > 50% in 733 Chinese patients admitted in the ICU 
[3]. Despite similar severity at baseline, day-28 mortal-
ity were 26% in the whole cohort and 30% in our patients 
intubated at day-1, a rate close to that reported in the 
large LUNG-SAFE study [17]. Different characteristics of 
patients admitted to ICUs and different degrees of stress 
on healthcare systems could explain these discrepancies 
[26]. Besides, we report a progressive decrease in 90-day 
mortality over the study period with a higher proportion 
of patients on high flow oxygen and non-invasive ventila-
tion and a lower rate of intubation on ICU day-1 in the 
last period of the study (Table  S5 and Figure S3). Simi-
lar findings have been reported by other groups [27] and 
might reflect better knowledge of the pathophysiology of 
the disease over time and less reluctance to use non-inva-
sive oxygenation strategies. It should however be noticed 
that duration of invasive mechanical ventilation and 
length of ICU and hospital stays were substantially longer 
than those of in ARDS unrelated to COVID-19. For 
instance, ICU length of stay in patients surviving severe 
ARDS was 26 (13–43) days, compared to 14 (7–23) days 
in the LUNG-SAFE study [17]. These patients rapidly 
overwhelmed ICU’s capacity, forcing a major reorganiza-
tion of ICU beds during the crisis [28].
Identifying the determinants of outcomes of critically 
ill patients with severe COVID-19 is crucial to optimize 
Table 3 Outcome of  patients on  mechanical ventilation (invasive or non‑invasive) according to  Acute Respiratory Dis‑
tress Syndrome Severity assessed the first day in the ICU
Results are expressed as n (%) or median (25th–75th percentiles)
ARDS acute respiratory distress syndrome, ICU intensive care unit
a Only patients on invasive mechanical ventilation or non-invasive ventilation within the first 24 h in the ICU
b Defined as 200 mmHg < PaO2/FIO2 ≤ 300 mmHg with PEEP ≥ 5 cm  H2O or continuous positive airway pressure ≥ 5 cm  H2O
c Defined as 100 mmHg < PaO2/FIO2 ≤ 200 mmHg with PEEP ≥ 5 cm  H2O
d Defined as  PaO2/FIO2 ≤ 100 mmHg with PEEP ≥ 5 cm  H2O
e p global value
Parameter No. Alla 
(n = 2233)
Mild  ARDSb 
(n = 539)
Moderate  ARDSc 
(n = 1154)
Severe  ARDSd 
(n = 540)
P  valuee
Progression of ARDS severity, No 
(%) [95 CI]






 Progression to  moderatec 237 
(44) [40–48]
– –





Duration of invasive ventilation, 
days
1448
 All patients 12 (7–17) 11 (6–17) 12 (7–17) 11 (6–17) 0.021
 Surviving patients at day-90 13 (8–18) 12 (6–18) 14 (8–18) 14 (10–19) 0.007
ICU length of stay, days 2187
 All patients 16 (9–28) 15 (8–27) 17 (9–28) 16 (8–30) 0.149
 Surviving patients at day-90 21 (13–36) 18 (10–31) 21 (13–35) 26 (16–43) < 0.001
ICU mortality 2214 773 (35) 146 (27) 366 (32) 261 (49) < 0.001
Hospital length of stay, days 2041
 All patients 23 (12–39) 22 (13–39) 24 (13–40) 22 (9–36) 0.002
 Surviving patients at day-90 30 (20–48) 28 (17–47) 31 (20–47) 32 (23–49) 0.012
Hospital mortality 2086 797 (38) 154 (30) 375 (35) 268 (53) < 0.001
 Still in the hospital at day-28 1152 (53) 286 (54) 628 (56) 238 (45) < 0.001
Day-28 mortality 2233 703 (31) 134 (25) 331 (29) 238 (44) < 0.001
Day-60 mortality 2233 808 (36) 157 (29) 382 (33) 269 (50) < 0.001
Day-90 mortality 2233 820 (37) 162 (30) 388 (34) 270 (50) < 0.001
the use of ICU care and other hospital resources. Older 
age, obesity, diabetes, being immunocompromised, 
lower  PaO2/FiO2 and higher hemodynamic and renal 
SOFA score at ICU admission were independently asso-
ciated with 90-day mortality, highlighting the dismal 
impact of premorbid conditions and multiorgan dam-
age on the outcomes of patients with the most severe 
forms of COVID-19 [3, 29]. The rate of patients with a 
BMI ≥ 30  kg/m2) was 41% in our cohort and unusu-
ally high compared to the prevalence of obesity in the 
French population [30]. More severe COVID-19 in obese 
patients may be explained by impairments in the adaptive 
immune response [31], cardiometabolic and thrombotic 
derangements [32], and alterations in lung function [33]. 
Obesity may also be a marker of poorer baseline health 
conditions since it is frequently associated with a lower 
socio-economic status [34]. As previously reported [35], 
a shorter time between first symptoms and ICU admis-
sion was also independently associated with increased 
mortality. Lastly, we and others [36, 37] observed an unu-
sually high rate of thromboembolic complications, with 
9% of proven pulmonary embolism. This rate may likely 
be higher since pulmonary CT angiography was not sys-
tematically performed in all patients. Diffuse vascular 
endothelium injury and intense activation of the coagu-
lation cascade may explain this increased risk of venous 
thrombosis [38].
Fig. 2 Kaplan–Meier survival estimates during the 90 days following ICU admission, according to A) Acute Respiratory Distress Syndrome Severity 
in patients on invasive mechanical ventilation or non-invasive ventilation at Day-1; B) age categories; C) ARDS severity progression within 7 days 
in patients with mild ARDS at Day-1*; D) ARDS severity progression within 7 days in patients with moderate ARDS at Day-1. *Only patients alive at 
day-7 were included in this analysis. ICU intensive care unit
The major strength of this study is the detailed report 
of physiological, clinical features, ventilatory manage-
ment, and 90-day outcomes of a large, multicenter series 
of 4244 critically ill COVID-19 patients. We acknowledge 
several limitations to our study. First, we conducted this 
cohort at a time where the national health system was 
extremely pressured with a need for a large number of 
ICU beds in some regions. Then, we cannot rule out that 
ICU admission policies and patients’ management were 
similar in all centers, although a sensitivity analysis intro-
ducing the center variable in the multivariable model 
found similar results. Second, testing was not standard-
ized across sites, which might have led to misclassifica-
tion. Third, some variables have missing data (as reported 
Table 4 Predictive patient factors associated with 90‑day mortality in critically ill adults with COVID‑19
BMI body mass index, CV cardiovascular, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, HR hazard ratio, CI confidence interval
a Complete analysis cases on 2152 patients
b Early effect before 14 days of follow-up (first line); late effects (i.e., after day-15) in the second line
c Calculated for all patients, including those on oxygen therapy using conversion tables provided in the online supplement
No. Univariate HR (95% CI) P value Multivariate HR (95% CI)a P value
Age, years 4244 1.05 (1.04–1.05) < 0.001 1.05 (1.04–1.06) < 0.001
Date of ICU admission 4244 < 0.001 0.311
 Before March, 15 – –
 From March, 16 to 31 0.69 (0.56–0.84) 0.86 (0.64–1.16)
 From April, 1 to 15 0.61 (0.50–0.76) 0.75 (0.54–1.04)
 After April, 16 0.54 (0.40–0.72) 0.82 (0.52–1.29)
Immunodeficiency 4192 1.64 (1.38–1.96) < 0.001 1.38 (1.06–1.80) 0.020
Body mass index, kg/m2b 3935 0.013 0.007
 < 25 – –
 25 ≤ BMI < 30 0.92 (0.68–1.25) 1.06 (0.78–1.43)
0.77 (0.57–1.03) 0.81 (0.60–1.10)
 30 ≤ BMI < 35 0.94 (0.68–1.29) 1.11 (0.80–1.55)
0.59 (0.42–0.83) 0.63 (0.44–0.89)
 35 ≤ BMI < 40 1.16 (0.79–1.69) 1.50 (1.02–2.21)
0.49 (0.30–0.79) 0.60 (0.37–0.97)
 ≥ 40 1.47 (0.93–2.33) 2.05 (1.28–3.27)
0.60 (0.32–1.14) 0.87 (0.45–1.66)
Active  smokingb 3935 1.51 (0.96–2.36) 0.225 1.30 (0.82–2.05) 0.314
0.87 (0.45–1.70) 0.71 (0.36–1.39)
Treated hypertension 4197 1.44 (1.29–1.60) < 0.001 1.01 (0.85–1.19) 0.940
Known diabetes 4196 1.62 (1.44–1.81) < 0.001 1.51 (1.28–1.78) < 0.001
Time between first symptoms to ICU admission, days 3862 < 0.001 0.010
 < 4 days – –
 4–7 days 0.87 (0.65–1.16) 1.07 (0.80–1.43)
 ≥ 8 days 0.52 (0.39–0.70) 0.73 (0.54–0.98)
During the first 24 h in the ICU
 CV component of the SOFA score ≥ 3 4065 1.77 (1.58–1.98) < 0.001 1.79 (1.52–2.11) < 0.001
 Renal component of the SOFA score ≥ 3b 4014 3.01 (2.30–3.92) < 0.001 2.38 (1.81–3.13) < 0.001
1.66 (1.11–2.48) 1.32 (0.87–2.01)
 Coagulation component of the SOFA score ≥ 3 4002 2.01 (1.21–3.34) 0.016 1.73 (0.81–3.69) 0.190
 PaO2/FiO2
c 3080 < 0.001 < 0.001
  200 < PaO2/FiO2 ≤ 300 0.94 (0.72–1.21) 0.93 (0.67–1.29)
  100 < PaO2/FiO2 ≤ 200 1.09 (0.87–1.38) 1.12 (0.83–1.51)
  PaO2/FiO2 ≤ 100 1.73 (1.36–2.19) 2.05 (1.51–2.78)
 Lymphocyte count ≤ 1 × 109/Lb 3481 0.92 (0.75–1.14) 0.008 0.80 (0.65–0.99) 0.030
1.46 (1.14–1.88) 1.24 (0.96–1.60)
pH 4003 0.67 (0.60–0.75) < 0.001 0.80 (0.65–0.97) 0.065
in the tables) due to a large number of patients included 
in a short period and intense clinical activity during the 
crisis. Indeed, our multivariable model included only 51% 
of the whole cohort of patients because of these missing 
data, which may explain, together with other residual 
confounders, the unanticipated lower mortality before 
14  days of follow-up associated with baseline lympho-
penia  [39, 40]. However, this association was no longer 
statistically significant in the model with multiple impu-
tations. Fourth, Grasselli et al. recently reported that high 
D-dimer concentration was significantly associated with 
mortality in COVID-19-related ARDS patients when 
associated with low values of static respiratory system 
compliance [22]. Unfortunately, we were unable to con-
firm that result in our multivariable model due to incon-
sistent collection of this data at ICU admission.
Conclusions
In this case series of 4244 critically ill patients with labo-
ratory-confirmed COVID-19 admitted to our ICUs, over-
all 90-day mortality was 31% and decreased over time 
during the study period. Mortality was higher in older 
patients, immunocompromised, extreme obese, diabet-
ics, those with a shorter delay between first symptoms 
and ICU admission, and those with extra-pulmonary 
organ dysfunction at ICU admission. Ninety-day mortal-
ity increased with the severity of ARDS from 30% in mild 
to 50% in severe ARDS. These information, together with 
the very long durations of mechanical ventilation and of 
ICU stay, which have contributed to the swamping of our 
ICU’s capacity, will be critical for the management of the 
second wave of the epidemic. Lastly, long-term follow-up 
is warranted to provide a complete description of the out-
comes and potential sequelae associated with the most 
severe forms of COVID-19 requiring ICU treatment.
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